US 11,883,491 B2
Compositions and methods for prevention and treatment of hearing loss
Jian Zuo, Omaha, NE (US); Fei Zheng, Memphis, TN (US); Tetsuji Yamashita, Memphis, TN (US); Zoe Kellard, West Sussex (GB); Tal Teitz, Omaha, NE (US); Jaeki Min, Memphis, TN (US); and Taosheng Chen, Germantown, TN (US)
Assigned to St. Jude Children's Research Hospital, Inc., Memphis, TN (US)
Appl. No. 16/610,170
Filed by ST. JUDE CHILDREN'S RESEARCH HOSPITAL, Memphis, TN (US)
PCT Filed Apr. 30, 2018, PCT No. PCT/US2018/030114
§ 371(c)(1), (2) Date Nov. 1, 2019,
PCT Pub. No. WO2018/204226, PCT Pub. Date Nov. 8, 2018.
Claims priority of provisional application 62/500,667, filed on May 3, 2017.
Prior Publication US 2020/0093923 A1, Mar. 26, 2020
Int. Cl. A61K 31/18 (2006.01); A61K 31/422 (2006.01); A61K 31/44 (2006.01); A61K 31/506 (2006.01); A61K 31/517 (2006.01); A61K 31/519 (2006.01); A61K 31/58 (2006.01); A61K 45/06 (2006.01); A61K 39/395 (2006.01); A61P 27/16 (2006.01); A61K 31/4706 (2006.01); A61K 31/4709 (2006.01); A61K 31/5377 (2006.01); A61K 31/713 (2006.01); A61K 38/17 (2006.01)
CPC A61K 39/3955 (2013.01) [A61K 31/18 (2013.01); A61K 31/422 (2013.01); A61K 31/44 (2013.01); A61K 31/4706 (2013.01); A61K 31/4709 (2013.01); A61K 31/506 (2013.01); A61K 31/517 (2013.01); A61K 31/519 (2013.01); A61K 31/5377 (2013.01); A61K 31/58 (2013.01); A61K 31/713 (2013.01); A61K 38/1709 (2013.01); A61K 45/06 (2013.01); A61P 27/16 (2018.01)] 8 Claims
 
1. A method for treating cisplatin-induced hearing loss comprising administering to an animal, in conjunction with cisplatin, an inhibitor of epidermal growth factor receptor (EGFR) signaling, wherein the hearing loss is associated with ototoxicity, wherein the inhibitor of EGFR signaling is selected from the group consisting of mubritinib, SNS314, dabrafenib and crenolanib.